Theme: Dynamic meeting poised to improve public health

HPV 2016

HPV 2016

ConferenceSeries Ltd invites all the participants from all over the world to attend ‘International Conference on Human Papillomavirus’ during October 20-21, 2016 in Chicago, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

In line with the of International Conference on Human Papillomavirus, addressing the most recent advances across the spectrum of Genital research from basic sciences to public health, Conference Highlights will Human Papillomavirus, HPV in Men, Cancer and HPV, Cervical Cancer, HIV – Human Immunodeficiency Virus, Genital Herpes, Syphilis, Hepatitis B, Chlamydia Infection, Gonorrhoea, Chancroid, Pelvic Inflammatory Disease, Other Genital Infections, Vaccines and Vaccination, Public Awareness.

ConferenceSeries Ltd Organizes 300+ Conferences Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 500+ Open access journals which contains over 50,000 eminent personalities, reputed scientists as editorial board members. 

Featuring 2 days of Scientific workshop, Special sessions, Speaker & Poster session, Industrial Expo. 300+ attendees from all over the world. 

Why attend???

As mentioned earlier,  Human Papilloma virus research, involves people from various disciplines and people form such various fields do not always get a chance to meet and discuss the current developments in their respective areas. HPV conferences seek to bring all such people together and thereby provide them a platform with which to discuss and exchange ideas with one another. The HPV conference is set to be graced by World-renowned speakers who will shed light on the most recent techniques, tactics, and the newest updates in Genital Infections & Human Papilloma virus Research.

Target Audience

·         Virologists

·         Immunologists

·         Microbiologists

·         Epidemiologists

·         Doctors

·         Public health planners

·         Primary Care Practitioners (Family Practice, Internal Medicine, General Practice)

·         Physician Assistants

·         Nurse Practitioners

·         Laboratory Professionals and

·         Healthcare professionals interested in screening, treating and counseling patients regarding infectious diseases.

ConferenceSeries Ltd invites all the participants from all over the world to attend ‘International Conference on Human Papillomavirus’ during October 20-21 in Chicago, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. 

In line with the of International Conference on Human Papillomavirus, addressing the most recent advances across the spectrum of Genital research from basic sciences to public health, Conference Highlights will Human Papillomavirus, HPV in Men, Cancer and HPV, Cervical Cancer, HIV – Human Immunodeficiency Virus, Genital Herpes, Syphilis, Hepatitis B, Chlamydia Infection, Gonorrhoea, Chancroid, Pelvic Inflammatory Disease, Other Genital Infections, Vaccines and Vaccination, Public Awareness

TRACK 1: Human Papillomavirus

Virology of Human Papillomavirus  is a double-stranded DNA, non-enveloped capsid virus. Their genome has three functional coding regions. Genome organization is similar for all papillomaviruses which has one strand transcribed. Epidemiology of HPV Infection causes warts, which are noncancerous skin growths known as cutaneous warts. Organization of life cycle can be divided into discrete phases. Initial infection requires access of infectious particles to cells in the basal layer, which for some HPV types is thought to require a break in the stratified epithelium. Toxicity and pathogenesis, Infection by specific HPV types has been linked to the development of cervical carcinoma. HPV infects epithelial cells that undergo terminal differentiation and so encode multiple mechanisms to override the normal regulation of differentiation to produce progeny virions.  The mechanism of HPV  is very complicated as it infects basal epithelial cells, which constitute the onlt cell layer in an epithelium that is actively dividing.

The estimated global HPV prevalence was found to be higher rates in sub-Saharan Africa (24%), Eastern Europe (21%) and Latin America (16%).

Related conferences on Human Papillomavirus

5th World Congress on Virology December 07-09, 2015 Atlanta, USA;7th World Congress on Virology November 21-23, 2016 Baltimore, USA; 3rd International Conference on HIV/AIDS, STDs & STIs, Nov 30-Dec 02, 2015, Atlanta, USA;4th International Conference on HIV/AIDS, STDS and STIS October 03-05, 2016 Miami, USA; 2nd World Congress on Infectious Diseases August 25-27, 2016 Philadelphia, USA  European Congress of Virology, Hamburg, Germany; American Society for Virology- Annual Meeting, Blacksburg, US; Virology, Buenos Aires, Argentina; ASM Conference on Infection and Cancer, Washington, US; Clinical Virology Symposium, Dayton Beach, Florida. 

TRACK 2: HPV Vaccines

The initial clinical trials for the HPV vaccine involved more than 20,000 women aged 16 to 26 from 33 countries. Trials showed that the vaccine is almost 100% effective in preventing abnormalities in cells in the cervix caused by high-risk HPV types 16 and 18. These abnormalities are a proven pre-cursor to cervical cancer. The HPV vaccine is recommended for preteen boys and girls at age 11 or 12 so they are protected before ever being exposed to the virus. HPV vaccine also produces the most infection-fighting cells, or antibodies, during the preteen years. Risks and hypersensitivity to HPV vaccines.  Therapeutic vaccines can be used to treat established HPV infections and could therefore have an immediate effect on the prevalence of HPV-associated malignancies. Therapeutic vaccine strategies aim to eliminate pre-existing lesions and even malignant tumors by generating cell-mediated immunity against HPV-infected cells. Live-vector-based vaccines can be classified into: i) bacterial vectors, such as Salmonella typhimurium and Listeria monocytogenes; and ii) viral vectors, such as adenovirus (AdV) and vaccinia virus. The use of vector-based vaccines for the delivery of antigen to dendritic cells (DC) is an appealing strategy for HPV vaccination. An Edible human papilloma virus vaccine obtained by culturing a transformant of an avirulent fission yeast host, wherein the transformant carries a gene encoding an antigenic protein of human papilloma virus introduced therein and accumulates the expressed antigenic protein in it. Safety and Immunogenicity of the Quadrivalent Human Papillomavirus Vaccine in HPV.  Vaccines storage and handling safety measures. A major step forward in helping protect millions of people in developing countries against HPV and cervical cancer.

Market Analysis report: Clinical trials involving more than 4,000 males aged 16 to 26 years from 18 countries showed the vaccine was 90% effective against HPV types 6, 11, 16 and 18 that cause genital warts and penile lesions, and 78% effective against HPV types 6, 11, 16 and 18 that cause anal lesions in men.

Related conferences on HPV vaccines

9th Global Summit and Expo on Vaccines & Vaccination November 30-December 02, 2015 San Francisco, USA; 13th Asia Pacific Global Summit and Expo on Vaccines & Vaccination November 10-12, 2016 Melbourne, Australia ; 10th Euro Global Summit and Expo on Vaccines & Vaccination June 16-18, 2016 Rome, Italy ;7th Middle East - Global summit and Expo on Vaccines & Vaccination, September 28-29, 2015 Dubai, UAE; 8th Indo Global summit and Expo on Vaccines, Therapeutics & Healthcare (VTH-2015) November 02-04, 2015 HICC, Hyderabad, India ; New Approaches to Vaccines for Human And Veterinary Tropical Diseases, Cape Town, South Africa; Vaccines, Lisbon, Portugal; Vaccine World Summit India Hyderabad, India; Annual World Congress of Vaccine Dalian, China; Vaccine Summit London, UK. 

TRACK 3: HPV Infection

Types of infection causes by papillomavirus. Warts are skin growths that are caused by the human papillomavirus. HPV stimulates quick growth of cells on the skin's outer layer. In most cases, common warts appear on the fingers, near the fingernails, or on the hands. Planter wartsSkin wartsGenital WartsFlat wartsSquamous cell PapillomaCervical dysplasia  refers to abnormal changes in the cells on the surface of the cervix. Respiratory papillomatosis known as Laryngeal papillomonas is characterized by the growth of tumours in the respiratory tract caused by HPV.  Epidermodysplasia verruciformis inherited disorder that predisposes patients to widespread HPV infection and cutaneous squamous cell carcinomas. Nonanogenital mucosal disease occurs in the nares, mouth, larynx and conjunctiva.

The overall prevalence of HPV in women is 22.5%. In men, the prevalence is 2-35% depending on the sexual practices of the population being studied.

Related conferences on HPV Infection

2nd World Congress on Infectious Diseases August 25-27, 2016 Philadelphia, USA; International Conference on Infectious Diseases & Diagnostic Microbiology, October3-5, 2016; International Conference on Oral, Mouth and Throat Cancer August 18-20, 2016 Portland, USA ;4th International Congress on Bacteriology and Infectious Diseases May 16-18, 2016 San Antonio, USA; 4th International Conference on HIV/AIDS, STDS and STIS October 03-05, 2016 Miami, USA;  Infectious Diseases Conference, Hyderabad, India;Annual Infectious Diseases Conference, Sacramento, California; Emerging Diseases and Surveillance Conference, Vienna, Austria; International Symposium on HIV & Emerging Infectious Diseases (ISHEID), Marseille, France;Annual Canadian Conference on HIV/AIDS Research (CAHR), Manitoba, Canada.

TRACK 4: HPV and Cancer

HPV found in the mouth and throat is called “Oral HPV.” Some types of oral HPV (known as “high risk types”) can cause cancers of the head and neck area. Other types of oral HPV (known as “low risk types”) can cause warts in the mouth or throat. Head and neck cancers that happen as a result of HPV infection occur in the part of the throat that includes the the base of the tongue and the tonsils. About 95 percent of anal cancers are caused by HPV. Most of these are caused by HPV type 16. HPV causes about 65 percent of vaginal cancers, 50 percent of vulvar cancers, and 35 percent of penile cancers. Most of these are caused by HPV type 16.

Cervical cancer: The most common HPV cancer. Almost all cervical cancer is caused by HPV.

Vulvar cancer: About 69% are linked to HPV.

Vaginal cancer: About 75% are linked to HPV.

Penile cancer: About 63% are linked to HPV.

Anal cancer: About 91% are linked to HPV.

Oropharyngeal cancers (cancers of the back of the throat, including the base of the tongue and tonsils): About 72% are linked to HPV.

Related conferences on HPV and Cancer

International Conference on Cervical Cancer September 22-23, 2016 Vienna, Austria ; 2nd International Conference on Prostate Cancer and Treatment May 05-07, 2016 Chicago, USA ;6th World Congress on Cancer Therapy December 01-03, 2016 Baltimore, USA;  International Conference on Oral, Mouth and Throat Cancer August 18-20, 2016 Portland, USA ;4th International Conference on HIV/AIDS, STDS and STIS October 03-05, 2016 Miami, USA;  Paediatric Oncology, Brussels, Belgium; Cancer Vaccines, Whistler, Canada; Changing Prospects for cancer, Manchester, UK; Asian Pacific Organisation for Cancer Prevention, Brisbane, Australia; Onco Update Europe, Budapest, Hungary.

TRACK 5: HPV- Cervical Cancer

Most women do not have any signs or symptoms of a precancer or early-stage cervical cancer. Symptoms usually do not appear until the cancer has spread to other tissues and organs. Also, symptoms may also be caused by a medical condition that is not cancer. Scope of the problem, In developed countries, programmes are in place which enable women to get screened, making most pre-cancerous lesions identifiable at stages when they can easily be treated. 5-year survival rates ranged from 93% for cancers detected early to 15% for cancers that were widespread.  Early treatment prevents up to 80% of cervical cancers in these countries. In developing countries, limited access to effective screening means that the disease is often not identified until it is further advanced and symptoms develop. The stage of cervical cancer refers to the extent to which it has spread. Survival rates are often based on previous outcomes of large numbers of people who had the disease.

In many developing nations cervical cancer is the leading cause of cancer mortality among women. Worldwide, it is the second most common cause of cancer mortality among women. Of the estimated more than 270 000 deaths from cervical cancer every year, more than 85% of these occur in less developed regions. Related conferences on HPV-Cervical Cancer

International Conference on Cervical Cancer September 22-23, 2016 Vienna, Austria ; 2nd International Conference on Gynecology & Obstetrics November 16-18, 2015 San Antonio, USA; Experts Meeting on Gynecologic Oncology May 19-21, 2016 San Antonio, USA ; 2nd International Conference on Gynecology & Obstetrics October 17-19, 2015 Dubai, UAE; International Conference on Oral, Mouth and Throat Cancer August 18-20, 2016 Portland, USA ;  Cancer Vaccines Masterclass Training London, United Kingdom; European Society of Gynaecological Oncology, Nice, France; Gynaecological Study Day, South Kensington, London, UK; Gynecology Oncology Conference, Barcelona, Spain; Cancer Study & Therapy Conference, Baltimore, USA.

TRACK 6: Cervical Cancer: Prevention and Early Detection

Several risks factors increase the chance of developing cervical cancer, which includes HPV infection, smoking, Immunosuppression, being overweight, long-term use of oral contraceptives, etc.,. HPV causes the production of 2 proteins known as E6 and E7 which turn off some tumor suppressor genes. This may allow the cervical lining cells to grow too much and to develop changes in additional genes, which in some cases will lead to cancer. Since the most common form of cervical cancer starts with pre-cancerous changes, there are 2 ways to stop or prevent  this disease from developing. One way is to find and treat pre-cancers before they become true cancers, and the other is to prevent the pre-cancers in the first place. Smoking develops squamous cell cervical cancer. Researchers have found cancer causing chemicals from cigarette smoke in the cervical mucus of women who smoke. One third of all cancer deaths in each year, are linked to diet and physical activity. Therefore to reduce the risk of developing certain types of cancers, its important to maintain diet and physical activity.

100% of cervical cases each year in the UK are linked to major lifestyle and other risk factors.

Cervical screening can prevent around 45% of cervical cancer cases in women in their 30s, rising with age to 75% in women in their 50s and 60s, who attend regularly.

For all stages of cervical cancer, the five-year survival rate is 68%. When detected at an early stage, the five-year survival rate for women with invasive cervical cancer is 91%. About 12,900 new cases of invasive cervical cancer will be diagnosed. About 4,100 women will die from cervical cancer.

TRACK 7: Cervical Cancer Treatment and Support

Common types of treatments for Cervical cancer include surgery, radiation therapy, chemotherapy, targeted-therapy. The stage of a cervical cancer is the most important factor in choosing treatment. However, other factors that affect this decision include the exact location of the cancer within the cervix, the type of cancer (squamous cell or adenocarcinoma), age, overall physical condition, and whether want to have children. Women treated for cervical cancer may experience a range of physical side effects and changes. They include bladder problems, bowel problems, lymphoedema, fertility problems and menopause. Having cervical cancer is physically draining, but it can also be emotionally draining as well. After the treatment for Cervical cancer, they have to follow-up. For some women with cervical cancer, treatment may remove or destroy the cancer. Completing treatment can be both stressful and exciting. You might be relieved to finish treatment, but find it hard not to worry about cancer coming back. Cancer survivors can be affected by a number of health problems, but often their greatest concern is facing cancer again. Some of the treatments can cause physical changes which can affect a women’s sexual life but many of these effects can be prevented or treated.

In US, 2.5 million women are estimated to have an annual cytological diagnosis of a low-grade cervical cancer precursor. The worldwide prevalence of HPV in cervical carcinoma is 95 to 99.7% and in anal cancer is 88%. In many lesser-developed countries, cervical cancer is the most common cancer among women due to the lack of effective screening programs that monitor cervical cytology by Pap smear. When diagnosed at its earliest stage, around 95% of women with cervical cancer will survive their disease for five years or more, compared with 5 in 100 of women when diagnosed at the latest stage.

TRACK 8: Cervical Cancer Vaccines

Three vaccines are available for the prevention of HPV-associated dysplasias and neoplasia, including cervical, vulvar, vaginal, and anal cancer; genital warts (condylomata acuminata); and precancerous genital lesions. Human papillomavirus vaccine, nonavalent (Gardasil 9), Human papillomavirus vaccine, quadrivalent (Gardasil), Human papillomavirus vaccine, bivalent (Cervarix). Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing. Safety of HPV vaccine during pregnancy, currently there are two inactive recombinant HPV vaccines available. Although the National Advisory Committee on Immunization recommends not using the vaccine in pregnant women, inadvertent exposures during pregnancy do occur. Recommended schedule for administering HPV vaccinedosage of vaccinevaccine seriesminimum intervals of doses of vaccines should be monitored. Contraindications may include History of a severe (anaphylactic) reaction to a vaccine component or following a previous dose and pregnancy. Advancement in HPV vaccines: Nine-valent HPV Vaccine May Prevent Nearly 90 Percent of Cervical Cancers.

Related conferences on Cervical Cancer Vaccines

International Conference on Cervical Cancer September 22-23, 2016 Vienna, Austria ; Experts Meeting on Gynecologic Oncology May 19-21, 2016 San Antonio, USA ;2nd International Conference on Gynecology & Obstetrics October 17-19, 2015 Dubai, UAE; 8th Indo Global summit and Expo on Vaccines, Therapeutics & Healthcare (VTH-2015) November 02-04, 2015 HICC, Hyderabad, India ; 13th Asia Pacific Global Summit and Expo on Vaccines & Vaccination November 10-12, 2016 Melbourne, Australia ;  Pregnancy vaccines Birmingham, UK; PDA/FDA Vaccines Conference Bethesda, Maryland; Cancer Vaccines Masterclass Training London, United Kingdom; European Society of Gynaecological Oncology, Nice, France; Gynaecological Study Day, South Kensington, London, UK.

TRACK 9: HPV in Men

Some of the 30 or so types of HPV associated with genital cancers can lead to cancer of the anus or penis in men. Both of these cancer types are rare, especially in men with a healthy immune system. To diagnose genital warts in men, the doctor will visually check a man's genital area to see if warts are present. Some doctors will apply a vinegar solution to help identify warts that aren't raised and visible. There is no treatment for HPV infection in men, when genital warts appear,treatments like radiationchemotherapy and surgery for anal cancer can be done. The HPV vaccine Gardasil, approved for use in females in 2006, was approved for males in 2009. More recently, the FDA approved Gardasil 9. Gardasil 9 is approved for use in males ages 9 to 15. Abstinence is the only sure way to prevent HPV transmission.

American Cancer Society estimates about 1,820 men in the U.S. will be diagnosed with cancer of the penis in 2015. About 2,640 men are estimated to have received a diagnosis of anal cancer in 2014 as well.

Related conference on HPV in Men

2nd International Conference on Prostate Cancer and Treatment May 05-07, 2016 Chicago, USA ;4th International Conference on HIV/AIDS, STDS and STIS October 03-05, 2016 Miami, USA; 4th International conference on Clinical Microbiology & Microbial Genomics, Oct 05-07, Philadelphia, USA; International Conference on Cancer Immunology and Immunotherapy July 28-30, 2016 Melbourne, Australia; 2nd World Congress on Infectious Diseases August 25-27, 2016 Philadelphia, USA ; International Congress on Men’s Health, New Delhi, India; Annual EAU Congress, Munchen, Germany; Congress of the Asia Pacific Initiative on Reproduction, Jakarta, Indonesia;Congress of the North Rhine-Westphalian Society of Urology, Munster, Germany; Reproduction Health Summit, London, UK. 

TRACK 10: Condylomata Acuminate

Condyloma acuminatum refers to an epidermal manifestation attributed to the epidermotropic Human Papillomavirus. Approximately 90% of condyloma acuminata are related to HPV types 6 and 11. Most patients with anal condylomata present with minor complaints. The most frequent complaint is that of perianal growth. Physical examination may reveal the classic cauliflower-like lesion. Due to the risk for communicability, as well as the risk for the development of squamous cell carcinoma, lesions should generally be treated. Treatment includes Folkloretopical methodsImmunologic MethodsSurgical Techniques.

Anogenital warts, or condylomata acuminata, are the most commonly diagnosed viral sexually transmitted disease (STD) in the US and the United Kingdom. The annual incidence is estimated to be between 500,000 and 1 million cases. 

Related conferences on Condylomata Acuminate

2nd World Congress on Infectious Diseases August 25-27, 2016 Philadelphia, USA ; International Conference on Infectious Diseases & Diagnostic Microbiology, October3-5, 2016; International Conference on Oral, Mouth and Throat Cancer August 18-20, 2016 Portland, USA ;International Conference on Cancer Immunology and Immunotherapy July 28-30, 2016 Melbourne, Australia;4th International conference on Clinical Microbiology & Microbial Genomics, Oct 05-07, Philadelphia, USA;  International Symposium on HIV & Emerging Infectious Diseases (ISHEID), Marseille, France; Annual Canadian Conference on HIV/AIDS Research (CAHR), Manitoba, Canada; Infectious Diseases Conference, Hyderabad, India; Individualized Medicine in Infectious Diseases: a Practical Approach, Tübingen, Germany; Management of Infections in Septic Shock Patients, Istanbul, Turkey; Infection Prevention and Control Conference, Tübingen, Germany.

TRACK 11: HPV Treatment

If the HPV infection has caused abnormal cell changes, there are main papilloma treatments like Cryotheraphy, which involves freezing the abnormal cells with liquid nitrogen. Conisation, a procedure also known as a cone biopsy, which removes the abnormal areas. Loop Electrosurgical Excision Procedure (LEEP), when the abnormal cells are removed with an electrical current. Surgeries to remove some abnormal cells from cervix. Alternatives to surgery are needed for the treatment of vulvar epithelial neoplasia is the treatment with imiquimod 5% cream, a topical immune response modulator. The effect of highly active Antiretroviral therapy on human papillomavirus clearance and cervical cytology.

The number of patients identified with HPV disease has increased markedly during the past 20 years due to heightened awareness of the various manifestations of HPV disease and to increased use of HPV DNA testing. 

Related conference on HPV treatment

4th International conference on Clinical Microbiology & Microbial Genomics, Oct 05-07, Philadelphia, USA; 5th World Congress on Virology December 07-09, 2015 Atlanta, USA;International Conference on Cancer Immunology and Immunotherapy July 28-30, 2016 Melbourne, Australia; 2nd International Conference on Retroviruses & Novel Drugs June 30-July 01, 2016 Cape Town, South Africa ;7th World Congress on Virology November 21-23, 2016 Baltimore, USA;6th World Congress on Cancer Therapy December 01-03, 2016 Baltimore, USA;  Viruses, Basel, Switzerland; Clinical Virology Symposium, Dayton Beach, Florida; Society for Virology, Munster, Germany; European Congress of Virology, Hamburg, Germany; American Society for Virology- Annual Meeting, Blacksburg, US

TRACK 12: Medications for HPV

Immune response modifiers have immunomodulatory effects and are used for treatment of external anogenital warts (EGWs) or condylomata acuminata. Keratolytic agents are used to aid in removal of keratin in hyperkeratotic skin disorders, including corns, ichthyoses, common warts, flat warts, and other benign verrucae.  Antineoplastics &  Antimetabolites interfere with nucleic acid synthesis and inhibit cell growth and proliferation.  New topical skin products like Sinecatechins which has gained FDA approval for genital warts. Complications of  HPV treatment are rare. They are generally confined to the HPV treatment site and include scarring and, in the case of genital warts, vulvodynia or hyperesthesia.

Related conferences on Medications for HPV

2nd International Conference on Retroviruses & Novel Drugs June 30-July 01, 2016 Cape Town, South Africa; International Conference on Cancer Immunology and Immunotherapy July 28-30, 2016 Melbourne, Australia;4th International conference on Clinical Microbiology & Microbial Genomics, Oct 05-07, Philadelphia, USA; 8th Indo Global summit and Expo on Vaccines, Therapeutics & Healthcare (VTH-2015) November 02-04, 2015 HICC, Hyderabad, India ;International Conference on Infectious Diseases & Diagnostic Microbiology, October3-5, 2016; Vaccine and ISV, Paris, France; Drug Discovery For Parasitic Diseases, Tahoe City, US; EUROGEN, Salzburg, Austria; Sexually Transmitted Diseases Research, Sydney, Australia; Current topics in Infectious Diseases; Grindelwald, Switzerland.

TRACK 13: Advances in HPV test

A prospective, randomized study was conducted to compare the effect of cryotheraphy and CO2 laser therapy in treatment of genital warts. Biomolecular diagnosis of HPV infection has gained an increasing consideration in the scientific and clinical community, mainly because of the very high sensitivity and very high NPV. HPV Screening With Triage by Novel BiomarkersNested PCR approach for detection and typing of epidermodysplasia verruciformis-associated human papillomavirus types in cutaneous cancers from renal transplant recipients. This nested PCR that enables the detection of all known EV HPV types at relatively low-copy-number levels. New screening strategies identifying epigenetic changes.

Related conferences on Advances in HPV

5th World Congress on Virology December 07-09, 2015 Atlanta, USA; Vaccine Summit London, UK;6th World Congress on Cancer Therapy December 01-03, 2016 Baltimore, USA; 13th Asia Pacific Global Summit and Expo on Vaccines & Vaccination November 10-12, 2016 Melbourne, Australia ; 8th Indo Global summit and Expo on Vaccines, Therapeutics & Healthcare (VTH-2015) November 02-04, 2015 HICC, Hyderabad, India ;International Conference on Infectious Diseases & Diagnostic Microbiology, October3-5, 2016;  Vaccines, Lisbon, Portugal; Annual World Congress of Vaccine Dalian, China; Pregnancy vaccines Birmingham, UK; PDA/FDA Vaccines Conference Bethesda, Maryland; Vaccine World CIS CEE  Moscow, Russian Federation.

 

Summary: HPV 2016 welcomes attendees, presenters, and exhibitors from all over the world to Chicago, USA. We are delighted to invite you all to attend and register for the International Conference on Human Genital Infections & HPV which is going to be held during October 20-21, 2016 at Chicago, USA. The organizing committee is gearing up for an exciting and informative conference program including plenary lectures, symposia, workshops on a variety of topics, poster presentations and various programs for participants from all over the world. We invite you to join us at the HPV-2016, where you will be sure to have a meaningful experience with scholars from around the world. All the members of HPV 2016 organizing committee look forward to meet you at Chicago, USA.

For more details please visit: hpv.conferenceseries.com 

Importance and scope

HPV is the most common sexually transmitted infection (STI). HPV is a different virus than HIV and HSV (herpes) and is a group of more than 150 related viruses. HPV is so common that nearly all sexually active men and women get it at some point in their lives. There are many different types of HPV. Some types can cause health problems including genital warts and cancers. But there are vaccines that can stop these health problems from happening.

HPV is named for the warts (papillomas) some HPV types can cause. Some other HPV types can lead to cancer, especially cervical cancer. There are more than 40 HPV types that can infect the genital areas of males and females. More than 80% of American women will have contracted at least one strain of HPV by age fifty. Although most women infected with genital HPV will not have complications from the virus, worldwide there are an estimated 529,000 new cases of cervical cancer and 275,000 deaths per year.About 85 percent of cancers, and 80% of deaths from cervical cancer occur in developing countries.

About 79 million Americans are currently infected with HPV. About 14 million people become newly infected each year. FDA has approved vaccines that prevent certain diseases, including cervical cancer, caused by some types of HPV.

Why Chicago?

ChicagoHClub was formed as a social group for those in Chicago and suburbs with Herpes and HPV. In recognition of January as Cervical Cancer Awareness Month, the Chicago Department of Public Health (CDPH) announces a new plan to increase human papillomavirus (HPV) vaccination coverage levels among Chicago adolescents as part of the department's ongoing efforts to decrease cancer rates across the city.The new plan includes in-person training for 200 medical providers, a new patient reminder system and a citywide public education campaign geared toward adolescents and their parents. The new plan is made possible through an $800,000 grant awarded to CDPH from the Centers for Disease Control and Prevention (CDC) following a competitive bidding process.

Conference highlights

1.       Human Papillomavirus

2.       HPV vaccines

3.       HPV Infection

4.       HPV Treatment

5.       Medication for HPV

6.       HPV-Cervical Cancer

7.       HPV in Men

8.       HPV-Cancer

9.       Condylomata Acuminate

10.   Advances in HPV test

11.   Cervical Cancer Vaccines

Why attend???

As mentioned earlier, Human Papilloma virus research, involves people from various disciplines and people form such various fields do not always get a chance to meet and discuss the current developments in their respective areas. HPV conferences seek to bring all such people together and thereby provide them a platform with which to discuss and exchange ideas with one another. The HPV conference is set to be graced by World-renowned speakers who will shed light on the most recent techniques, tactics, and the newest updates in Human Papilloma virus Research.

Major Virology Associations around the Globe

American Society for Virology 

European Society for Clinical Virology 

Hellenic Society of Virology

Danish Society for Virology

Pan American Society for Clinical Virology

International Society for Influenza and Other Respiratory Virus Diseases

International Society for Antiviral Research 

Hospitals in Chicago

Figure 1: Chicago has a total of 118 hospitals .41 of these hospitals are amongst the most highly ranked in the United States for their overall operations. Besides these 41 hospitals there are others which rank high for a particular department.

Source reference 1

Top associations of HPV in USA

Centers for Disease Control and Prevention(CDC)

Foundation for Women’s Cancer

Chicago Health

Women's Center for Health

Crossroads of the Illinois Conservative Community

World Health Organisation

American Cancer Society

U.S. Department of Health and Human services

American Sexual Health Association

Reference 2 to 10

Universities and labs associated with HPV research all over the globe

Figure 2: Institutes with Virology Departments

reference 11

Figure 3:  Standalone Virology Labs worldwide

Reference 12                                                                                           

Deaths per year due to HPV-related cancer:

Reference 12-1

Global Cervical Cancer Screening Market:

The global cervical cancer screening market was approximately $15 billion in 2014 and is estimated to grow at a CAGR of 7.0% to reach nearly $22 billion by 2020. PAP test is the largest segment of the global market. However, HPV/co-test will be the fastest-growing product segment during the forecast period.

 

Reference 12-2

 

Global scenario of HPV:

Reference 12-3

 

Deaths per day due to HPV

In the US, if there are 6100 HPV cancer deaths per year, that's 16 per day, or one per 90 minutes.

For the world, there are more than 295,000 HPV cancer deaths per year, or 808 per day, or one per two minutes.

 

Glance at Market of HPV Related Products:

Currently, there are different strategies to increase the rate of HPV prevention from various angles. Researchers have been looking into ways to increase cross-protections against various types of HPV, to enhance the half-life and decrease the number of vaccinations. At least 40 countries had implemented HPV vaccination in their national immunization programs (NIPs) by the beginning of 2012. Among these countries, the United States, the UK, Canada, and Australia were the first countries to execute the implementation. In 2007, only 3 European countries had introduced HPV vaccine which then increased to 22 countries who had introduced the vaccine into their NIPs.

Market growth of HPV related activities:

Figure 5: No of conferences held on HPV

Reference 13 to 29

Companies that produce HPV vaccines (USA)

BioPharmGuy

InterveXion Therapeutics

Novartis Diagnostics

TM3 Therapeutics

Bavarian Nordic

ImmunoScience

Juvaris

Tolerion

Adamis Pharmaceuticals

BioMedicure

Inovio PharmaceuticaL

Reference  30

Drugs used to treat HPV:

1. Gardasil is one of the top drugs for the HPV virus. It is a non-infectious quadrivalent recombinant vaccine, with highly purified virus-like particles, in combination with an aluminum-containing vaccine adjuvant.

 2. Imiquimod (Aldara) is a prescription medication that acts as an immune response modifier. Imiquimod is a patient-applied cream used to treat certain diseases of the skin as well as HPV.

3. Podofilox(Condylox) is a drug used to treat the HPV virus. It is a non-alkaloid toxic lignan extracted from the roots and rhizomes of the podophyllum species. It is a topical gel used for the treatment of external genital and perianal exophytic warts (condylomata acuminata) caused by the human papillomavirus (HPV).

4. Trichloroacetic acid is an analogue of acetic acid in which three hydrogen atoms of the methyl group have all been replaced by chlorine atoms. Solutions containing trichloroacetic acid as an ingredient are used for the treatment of genital warts, caused by some type of HPV.

 5. A new study has found that the human papillomavirus (HPV) vaccine protects against the sexually transmitted virus that causes cervical cancer.  It also helps prevent genital warts and low-grade cervical growths.

The following drugs and medications are in some way related to, or used in the treatment of Human Papilloma Virus. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Tagamet

Aldara

Resinol

Pododerm

Podocon-25

Tagamet HB

The above list is just a representation of some of the drug classes used to treat influenza and is in no way meant to be an exhaustive list.

Reference 31

Reference 32

Funding allotment

The American Cancer Society dedicates $7 million each year to fund prevention research. The National Cancer Institute’s (NCI) investment in cervical cancer research decreased from $83.3 million to $70.8 million between fiscal years (FY) 2006 and 2009 before increasing again to $76.5 million in FY 2010. In addition, NCI supported $14.3 million in cervical cancer research in FY 2010 and 2014using funding from the American Recovery and Reinvestment Act (ARRA). Health and Human Services (HHS) Secretary Kathleen Sebelius announced that US is allocating $1 billion in existing funds to purchase large quantities of vaccine against the novel influenza strain and HPV Vaccines.

 

Reference 33and 34

 

 

References

1.        http://health.usnews.com/best-hospitals/area/chicago-il

2.        http://www.cdc.gov/vaccines/pubs/surv-manual/chpt05-hpv.html

3.        http://www.foundationforwomenscancer.org/questions-from-readers-hpv-duration/

4.        http://chicagohealthonline.com/health-mastery-2/

5.        http://www.womenscenterforhealth.org/blog/2012/10/pap-smear-and-high-risk-hpv-why-both-how-often/

6.        http://illinoisreview.typepad.com/illinoisreview/hpv_vaccination/

7.        http://www.who.int/bulletin/volumes/85/9/06-038414/en/

8.        http://www.cancer.org/

9.        http://www.niaid.nih.gov/Pages/default.aspx

10.     http://www.ashastd.org/

11.     http://virology.net/garryfavweborg.html

12.     http://virology.net/garryfavwebvirlabs.html

12-1   http://www.cdc.gov/cancer/hpv/statistics/cases.htm

12-2   http://www.kegel.com/hpv/deaths/

12-3   http://www.kegel.com/hpv/deaths/

13.     http://www.icgeb.org/argentina-workshop-human-papillomavirus-2014.html

14.     http://ecancer.org/conference/calendar/586-8th-stop-cervical-breast-and-prostate-cancer-in-africa-conference.php

15.     http://www.eventsecalendar.com/event/HPV-2014-Seattle-29th-International-Papillomavirus-Conference-10013

16.     http://hpv2015.org/

17.     http://www.primeoncology.org/online_education/solid_tumor/2015/webcast-gynconference2015/session-1/mahner.aspx

18.     http://conference.ncri.org.uk/hpv/

19.     http://www.eurogin.com/2015/

20.     http://10times.com/cervical-cancer-and-hpv

            21.   https://www.charite-mayo.de/thursday.html

            22.   http://www.cancer.dk/research/Symposium/

            23.   http://www.methodistcollege.edu/professional-development/course-calendar/2015-head-and-neck-cancer-symposium-management-of-oral-pharyngeal-cancers

            24.   http://www.mdlinx.com/oncology/conference-details.cfm/104928/

            25.   http://www.mdlinx.com/oncology/conference-details.cfm/166828/

            26.   http://www.stjohnprovidence.org/upload/docs/Health%20Professionals/Conferences/head-and-neck-cancer/head-and-neck-cancer-conference.pdf

            27.   http://www.aacr.org/Meetings/Pages/MeetingDetail.aspx?EventItemID=63#.VZ0cFzjNtMs

            28.   http://www.nfid.org/acvr

            29.   http://ipvsoc.org/conferences

            30.   http://biopharmguy.com/links/company-by-location-vaccines.php

            31.   http://www.drugs.com/condition/human-papilloma-virus.html

            32.   http://www.newsmax.com/FastFeatures/HPV-drugs-treatment-options/2011/03/24/id/370240/

            33.   http://www.virology.ws/2009/05/25/us-to-redirect-1-billion-to-study-adjuvant-for-influenza-vaccine/

            34.   http://www.nano.gov/sites/default/files/2015_nni_historical_agency_funding_chart2_small.jpg

 

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date October 20-21, 2016
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Closed Day 1 Day 2
Poster Opportunity Closed Click Here to View